Article thumbnail

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register

By Rebecca Davies, James B Galloway, Kath D Watson, Mark Lunt, Deborah P M Symmons and Kimme L Hyrich
Topics: Clinical and Epidemiological Research
Publisher: BMJ Group
OAI identifier: oai:pubmedcentral.nih.gov:3168333
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum
  2. (2009). Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng
  3. Autoantibody profi le in rheumatoid arthritis during long-term infl iximab treatment. Arthritis Res Ther
  4. (2001). Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between
  5. (2010). Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology
  6. (2010). Etanercept and venous thromboembolism: a case series.
  7. (1999). Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.
  8. (2002). Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum
  9. (2006). Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum
  10. (1999). Infl iximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial.
  11. (1990). Rheumatoid arthritis and hypercoagulable state.
  12. (2009). Rheumatoid arthritis and thrombosis. Clin Exp Rheumatol
  13. (2007). Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med
  14. (2011). Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register . Ann Rheum Dis
  15. (2004). Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf
  16. (1997). The association of malignancy with rheumatic and connective tissue diseases. Semin Oncol
  17. (2008). The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology
  18. (2006). The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism.